Your Health, We Care
Release date: 2024-08-27 15:41:14 Recommended: 126
As the first oral small molecule drug for HR/HER2- and PIK3CA-mutated advanced breast cancer, Alpelisib effectively prolongs the progression-free survival of patients by inhibiting the PI3K signaling pathway, bringing more treatment options.
Understanding drug interactions is essential to avoid adverse effects. Here's information about how Alpelisib may interact with other medications.
The use of Alpelisib with strong CYP3A4 inducers may reduce the concentration of the drug and weaken the therapeutic effect. Concomitant use with strong CYP3A4 inducers should be avoided, or alternative agents with less effect on CYP3A4 should be chosen.
In combination with breast cancer resistance protein (BCRP) inhibitors, it may increase the concentration of Alpelisib, increasing the risk of toxicity. Concomitant use of BCRP inhibitors during the use of Alpelisib should be avoided and, if unavoidable, close monitoring for possible side effects.
Understanding these drug interactions can help optimize treatment outcomes and reduce medication risks. Next, we will introduce the therapeutic effects of Alpelisib.
For the dosage and dosage of Alpelisib, please learn about the following dosage recommendations.
If you miss a dose of Alpelisib, you can retake the dose within 9 hours of taking it, preferably with a meal, to help absorb the drug. If it is more than 9 hours, the dose for the day should be skipped, and the usual medication should be resumed at the normal time the next day.
If vomiting occurs after taking the drug, you should not take an additional dose on the same day, and you should continue taking the medicine the next day at the normal time, following the established medication schedule.
Proper management of missed doses and vomiting can ensure continuity of treatment. Next, we will discuss the common adverse drug reactions of Alpelisib and how to deal with them.
Some adverse reactions may occur during the course of medication, and common side effects include but are not limited to the following.
Medications can affect the immune system, causing a decrease in lymphocyte counts. May increase the risk of infection or worsen existing infection.
Drugs can cause liver cell damage, leading to increased levels of ALT. Liver function needs to be monitored regularly to prevent serious liver problems.
Monitor lymphocyte count and liver function regularly so that these adverse effects can be detected and managed in a timely manner.
[Warm tips] During the use of Alpelisib, please check the lymphocyte count and liver function regularly to detect and deal with potential side effects in time.
